Every profession has an essential, behind-the-scenes component without which it cannot function. Medicine is no exception. Pathologists are one of medicine’s group of specialists whose work as diagnosticians is critical for patient care. This article describes the multifaceted role that pathologists play in oncology practice and cancer research. To do so, we will highlight the role of pathologists in a typical “day-in-the-life” of a patient’s journey in cancer care. Clinicians, clinical trialists, radiologists, researchers, and pathologists, all work together to provide optimal, multidisciplinary care for patients with cancer.
Bibliographical noteFunding Information:
A.M. De Marzo reports grants from Janssen R&D and personal fees from Cepheid Inc and Merck outside the submitted work. J. Debnath reports personal fees from Vescor and Merck outside the submitted work. K.D. Eaton reports grants from Mirati Therapeutics and personal fees from Lilly outside the submitted work. K. Elenitoba-Johnson reports grants from Thermofisher outside the submitted work. C.A. French reports grants, personal fees, and other support from Boehringer-Ingelheim and Glaxo-Smith-Kline, grants from c4 Therapeutics, and other support from Daichi-Sanyo and Vertex outside the submitted work. T.J. Fuchs reports personal fees and other support from Paige.ai Inc. outside the submitted work. J. Huang reports personal fees from Kingmed, MoreHealth, OptraScan, Genetron, Omnitura, York Biotechnology, Genecode, VIVA Biotech, Sisu Pharma, and Vetonco and grants from Zenith Epigenetics, BioXcel Therapeutics, and Fortis Therapeutics outside the submitted work. A. Iafrate reports other support from ArcherDx and personal fees from Kinnate Therapeutics, Repare Therapeutics, PAIGE.AI, and Oncoclinicas Brasil during the conduct of the study; in addition, A. Iafrate has a patent for Anchored Multiplex PCR licensed and with royalties paid from ArcherDx. M. Loda reports other support from Methylex outside the submitted work. R.G. Lorenz reports other support from Genentech, Inc. outside the submitted work. T.L. Lotan reports grants from Roche/Ventana, DeepBio, and Myriad outside the submitted work. A. Maitra reports other support from Cosmos Wisdom Biotechnology and Thrive Earlier Detection, an Exact Sciences Company, and personal fees from Freenome outside the submitted work. G.A. Meijer reports other support from Hartwig Medical Foundation, Sysmex, and Exact Sciences and grants from CZ Health Insurance outside the submitted work; in addition, G.A. Meijer has several patents pending and is co-founder and board member (CSO) of CRCbioscreen BV. G.A. Meijer also has research collaborations with Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics (PGDX) and Hartwig Medical Foundation: these companies/foundations provide materials, equipment and/or sample/genomic analyses. E. Pikarsky reports personal fees from Roche and MSD outside the submitted work. J.S. Reis-Filho reports personal fees from Paige.AI during the conduct of the study, as well as personal fees from Repare Therapeutics, Goldman Sachs, Grupo Oncoclinicas, Roche Tissue Diagnostics, Novartis, Genentech, Roche, In Vicro, Eli-Lilly, and Personalis outside the submitted work. A.L. Richardson reports a patent for NtAI for Myriad Genetics for MyChoice HRD test licensed and with royalties paid from Myriad Genetics. L.D. True reports being co-founder of LightSpeed Microscopy, Inc. and holding equity in the company. No disclosures were reported by the other authors.
© 2021 American Association for Cancer Research.
- Medical Oncology